Armin Ghobadi, MD, on Recent Advancements in the Treatment of Patients with DLBCL

News
Video

An expert in the treatment of diffuse large B-cell lymphoma explained some of the exciting advances in treatment and hypothesized what comes next after the 2020 ASH Annual Meeting & Exposition.

In an interview with CancerNetwork®, Armin Ghobadi, MD, of the Washington University School of Medicine in St. Louis, explained some of the exciting advances in the treatment of diffuse large B-cell lymphoma (DLBCL) and hypothesized what’s to come following the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.

Transcription:

There have been a lot of advances in treatment of DLBCL, including multiple T-cell engagers and CAR [chimeric antigen receptor] T-cell [therapies] going after CD19, [CD]20, or other targets. The research in this field is expanding rapidly and dramatically.

Even when you use CAR T-cell therapy—that’s the most effective treatment for relapsed/refractory DLBCL—long-term survival, at least 2 to 3 years disease-free survival [rates are] 35% to 40%. And those patients that relapse don’t have good options. There is still a need for improvement there, especially combining these interesting modalities the same way that we combined CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone], to come up with a good strategy to cure patients with DLBCL. Combining these newer modalities of T-cell engagers, CAR T-cell [therapies], antibodies drug conjugates, and those kinds of things all together early on for patients that did relapse early [may be necessary] to cure more patients.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content